These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 3107574)
1. Lethal and sublethal effects of the combination of doxorubicin and the bisdioxopiperazine, (+)-1,2,-bis (3-5-dioxopiperazinyl-1-yl) propane (ICRF 187), on murine sarcoma S180 in vitro. Wadler S; Green MD; Basch R; Muggia FM Biochem Pharmacol; 1987 May; 36(9):1495-501. PubMed ID: 3107574 [TBL] [Abstract][Full Text] [Related]
2. Synergistic activity of doxorubicin and the bisdioxopiperazine (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF 187) against the murine sarcoma S180 cell line. Wadler S; Green MD; Muggia FM Cancer Res; 1986 Mar; 46(3):1176-81. PubMed ID: 3080237 [TBL] [Abstract][Full Text] [Related]
3. Potentiation of doxorubicin cytotoxicity by (+)-1,2-bis-(3,5-dioxopiperazinyl-1-yl) propane (ICRF-187) in human leukemic HL-60 cells. Monti E; Sinha BK Cancer Commun; 1990; 2(4):145-9. PubMed ID: 2164412 [TBL] [Abstract][Full Text] [Related]
4. Studies in mice treated with ICRF-159 combined with daunorubicin or doxorubicin. Giuliani F; Casazza AM; Di Marco A; Savi G Cancer Treat Rep; 1981; 65(3-4):267-76. PubMed ID: 6263470 [TBL] [Abstract][Full Text] [Related]
5. Effects of the L isomer (+)-1,2-bis(3,5-dioxopiperazine-1-yl)propane on cell survival and cell cycle progression of cultured mammalian cells. Traganos F; Darzynkiewicz Z; Melamed MR Cancer Res; 1981 Nov; 41(11 Pt 1):4566-76. PubMed ID: 6171341 [TBL] [Abstract][Full Text] [Related]
6. Bisdioxopiperazine, (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF 187), enhances the antiproliferative effect of cisplatin on human ovarian cancer cells. Scambia G; Della Bitta R; Benedetti Panici P; De Vincenzo R; Contu G; Ercoli A; Bonanno G; Pierelli L; Mancuso S Gynecol Oncol; 1995 Apr; 57(1):16-22. PubMed ID: 7705696 [TBL] [Abstract][Full Text] [Related]
7. Role of (+-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) in modulating free radical scavenging enzymes in doxorubicin-induced cardiomyopathy. Alderton P; Gross J; Green MD Cancer Res; 1990 Aug; 50(16):5136-42. PubMed ID: 2116226 [TBL] [Abstract][Full Text] [Related]
8. The cytokinetic and cytotoxic effects of ICRF-159 and ICRF-187 in vitro and ICRF-187 in human bone marrow in vivo. Wheeler RH; Clauw DJ; Natale RB; Ruddon RW Invest New Drugs; 1983; 1(4):283-95. PubMed ID: 6432722 [TBL] [Abstract][Full Text] [Related]
9. Comparison of the effectiveness of (+/-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) and N-acetylcysteine in preventing chronic doxorubicin cardiotoxicity in beagles. Herman EH; Ferrans VJ; Myers CE; Van Vleet JF Cancer Res; 1985 Jan; 45(1):276-81. PubMed ID: 3917371 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy. Martin E; Thougaard AV; Grauslund M; Jensen PB; Bjorkling F; Hasinoff BB; Tjørnelund J; Sehested M; Jensen LH Toxicology; 2009 Jan; 255(1-2):72-9. PubMed ID: 19010377 [TBL] [Abstract][Full Text] [Related]
11. Influence of ICRF-159 or ICRF-186 on cytotoxicity of daunorubicin and doxorubicin. Supino R Tumori; 1984 Apr; 70(2):121-6. PubMed ID: 6730012 [TBL] [Abstract][Full Text] [Related]
12. Effects of ICRF-186 [(L)1,2-bis(3,5-dioxopiperazinyl-1-yl)propane] on the toxicity of doxorubicin in spontaneously hypertensive rats. Zhang J; Herman EH; Ferrans VJ Toxicology; 1994 Sep; 92(1-3):179-92. PubMed ID: 7940559 [TBL] [Abstract][Full Text] [Related]
13. Antagonistic effect of the cardioprotector (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etoposide (VP-16). Sehested M; Jensen PB; Sørensen BS; Holm B; Friche E; Demant EJ Biochem Pharmacol; 1993 Aug; 46(3):389-93. PubMed ID: 8394080 [TBL] [Abstract][Full Text] [Related]
14. Cell cycle progression and chromosome segregation in mammalian cells cultured in the presence of the topoisomerase II inhibitors ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane; ADR-529] and ICRF-159 (Razoxane). Gorbsky GJ Cancer Res; 1994 Feb; 54(4):1042-8. PubMed ID: 8313360 [TBL] [Abstract][Full Text] [Related]
15. The hydrolysis activation of the doxorubicin cardioprotective agent ICRF-187 [+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane). Hasinoff BB Drug Metab Dispos; 1990; 18(3):344-9. PubMed ID: 1974197 [TBL] [Abstract][Full Text] [Related]
16. ICRF 159-induced cell-cycle perturbation in vitro: its relationship to inhibition of colony-forming ability. Edgar DH; Creighton AM Br J Cancer; 1981 Aug; 44(2):236-40. PubMed ID: 7023524 [TBL] [Abstract][Full Text] [Related]
17. The protective activity of ICRF-187 against doxorubicin-induced cardiotoxicity in the rat. Yeung TK; Jaenke RS; Wilding D; Creighton AM; Hopewell JW Cancer Chemother Pharmacol; 1992; 30(1):58-64. PubMed ID: 1586981 [TBL] [Abstract][Full Text] [Related]
18. The iron(III) and copper(II) complexes of adriamycin promote the hydrolysis of the cardioprotective agent ICRF-187 ((+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane). Hasinoff BB Agents Actions; 1990 Mar; 29(3-4):374-81. PubMed ID: 2160191 [TBL] [Abstract][Full Text] [Related]
19. Enhancement of the effectiveness of daunorubicin (NSC-82151) or adriamycin (NSC-123127) against early mouse L1210 leukemia with ICRF-159 (NSC-129943). Woodman RJ; Cysyk RL; Kline I; Gang M; Venditti JM Cancer Chemother Rep; 1975; 59(4):689-95. PubMed ID: 1175163 [TBL] [Abstract][Full Text] [Related]
20. Reduction of chronic doxorubicin cardiotoxicity in beagle dogs by bis-morpholinomethyl derivative of razoxane (ICRF-159). Herman EH; Ferrans VJ; Bhat HB; Witiak DT Cancer Chemother Pharmacol; 1987; 19(4):277-81. PubMed ID: 3594714 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]